ӳ��ý

DNA hypermethylation of MED1 and MED23 as early diagnostic biomarkers for unsolved issues in atrial fibrillation.

Schiano C, Infante T, Benincasa G, et al. DNA hypermethylation of MED1 and MED23 as early diagnostic biomarkers for unsolved issues in atrial fibrillation. International journal of cardiology. 2025:133179. doi:10.1016/j.ijcard.2025.133179

Bi-allelic MED16 variants cause a MEDopathy with intellectual disability, motor delay, and craniofacial, cardiac, and limb malformations.

Guillouet C, Agostini V, Baujat G, et al. Bi-allelic MED16 variants cause a MEDopathy with intellectual disability, motor delay, and craniofacial, cardiac, and limb malformations. American journal of human genetics. 2025. doi:10.1016/j.ajhg.2025.02.016

Clinical, pathologic, cytogenetic, and molecular profiling in self-identified black women with uterine leiomyomata.

Hayden MA, Ordulu Z, Gallagher S, et al. Clinical, pathologic, cytogenetic, and molecular profiling in self-identified black women with uterine leiomyomata. Cancer Genet. 2018;222-223:1-8. doi:10.1016/j.cancergen.2018.01.001

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.

Barbieri CE, Baca SC, Lawrence MS, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44(6):685-9. doi:10.1038/ng.2279

Genome-scale CRISPR-Cas9 knockout screening in human cells.

Shalem O, Sanjana NE, Hartenian E, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343(6166):84-7. doi:10.1126/science.1247005

Dissecting the regulatory circuitry of a eukaryotic genome.

Holstege FC, Jennings EG, Wyrick JJ, et al. Dissecting the regulatory circuitry of a eukaryotic genome. Cell. 1998;95(5):717-28.